Release Date: 14/12/18 08:32 Summary: Letter to Shareholders Price Sensitive: Yes Download Document 501.5KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%